CTMG has emerged as the first resource in the drug development industry to understand and to correct perhaps the biggest remaining challenge in Stage 2 - 3 trials: the essential impenetrable barrier between the Sponsor and the PI Site.
• Powerful New Evidence
• On-Site Patient Enrollment Experts
• Consistent, Sustained Recruitment Strategies
• Continuous Validation of Patient Profiles
• Front End Discipline of FDA Standards
As noted in an … [READ MORE]
• The murky space beyond the “Barrier”
• Watch out for the data trap
Can You Spot The Huge Trapdoor In Your Clinical Trial?
***Click the Images to the right for an Enlarged Captioned View***
CTMG has … [READ MORE]
• Insufficiency Of The Deeply Flawed SMO Model
• What’s It All About: The FDA!
• Why CTMG?
***Click the Images to the right for a Enlarged Captioned View***
The large reason for the "Black Hole" has been poor … [READ MORE]